Tetra Bio-Pharma (TBPM.Q) Stock Overview

A biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. More details

TBPM.Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($515)

Shares are highly illiquid

Latest financial reports are more than a year old

TBPM.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Tetra Bio-Pharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tetra Bio-Pharma
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	-99.90%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Shareholder Returns

	TBPM.Q	US Pharmaceuticals	US Market
7D	0%	-1.9%	0.3%
1Y	0%	22.6%	13.6%

Return vs Industry: TBPM.Q underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.

Return vs Market: TBPM.Q underperformed the US Market which returned 14.4% over the past year.

Price Volatility

Is TBPM.Q's price volatile compared to industry and market?
TBPM.Q volatility
TBPM.Q Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.4%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.0%

Stable Share Price: TBPM.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine TBPM.Q's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Richard Giguere	www.tetrabiopharma.com

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; and REBORN for the treatment of breakthrough cancer pain. It also develops novel prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acute Respiratory Distress Syndrome, sepsis and ophthalmic disease.

Tetra Bio-Pharma Inc. Fundamentals Summary

How do Tetra Bio-Pharma's earnings and revenue compare to its market cap?
TBPM.Q fundamental statistics
Market cap	US$515.00
Earnings (TTM)	-US$28.92m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is TBPM.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TBPM.Q income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$39.02m
Earnings	-CA$39.02m

Last Reported Earnings

Aug 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did TBPM.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/29 07:51
End of Day Share Price	2026/01/29 00:00
Earnings	2022/08/31
Annual Earnings	2021/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tetra Bio-Pharma Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Rahul Sarugaser	Paradigm Capital, Inc.

Tetra Bio-Pharma Inc.OTCPK:TBPM.Q Stock Report